{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:55:22Z","timestamp":1792439722520,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.humimm.2020.05.001","type":"journal-article","created":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T17:03:57Z","timestamp":1591031037000},"page":"354-360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Clinical utility of next generation sequencing based HLA typing for disease association and pharmacogenetic testing"],"prefix":"10.1016","volume":"81","author":[{"given":"Tracie","family":"Profaizer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Pole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Monds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter","family":"L\u00e1z\u00e1r-Moln\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humimm.2020.05.001_b0005","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1399-0039.2004.00327.x","article-title":"An update of the HLA genomic region, locus information and disease associations: 2004","volume":"64","author":"Shiina","year":"2004","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.humimm.2020.05.001_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/iji.12088","article-title":"HLA and disease: guilt by association","volume":"41","author":"Howell","year":"2014","journal-title":"Int. J. Immunogenet."},{"key":"10.1016\/j.humimm.2020.05.001_b0015","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-genom-091212-153455","article-title":"Major histocompatibility complex genomics and human disease","volume":"14","author":"Trowsdale","year":"2013","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/j.humimm.2020.05.001_b0020","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1128\/CMR.00048-08","article-title":"HLA and infectious diseases","volume":"22","author":"Blackwell","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.humimm.2020.05.001_b0025","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/iji.12332","article-title":"What has GWAS done for HLA and disease associations?","volume":"44","author":"Kennedy","year":"2017","journal-title":"Int. J. Immunogenet."},{"key":"10.1016\/j.humimm.2020.05.001_b0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002197","article-title":"Trans-eQTLs reveal that independent genetic variants associated with a complex phenotype converge on intermediate genes, with a major role for the HLA","volume":"7","author":"Fehrmann","year":"2011","journal-title":"PLoS Genet."},{"key":"10.1016\/j.humimm.2020.05.001_b0035","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.humimm.2020.05.001_b0040","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.humimm.2020.05.001_b0045","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.humimm.2020.05.001_b0050","unstructured":"FDA US: FDA Label for Abacavir. 2018."},{"key":"10.1016\/j.humimm.2020.05.001_b0055","unstructured":"FDA US: FDA Lable for Carbamazepine. 2018."},{"issue":"64","key":"10.1016\/j.humimm.2020.05.001_b0060","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"2012","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.humimm.2020.05.001_b0065","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1399-0039.2007.00840.x","article-title":"HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay","volume":"70","author":"Hammond","year":"2007","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.humimm.2020.05.001_b0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1399-0039.2011.01676.x","article-title":"Celiac disease and HLA typing using real-time PCR with melting curve analysis","volume":"78","author":"Profaizer","year":"2011","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.humimm.2020.05.001_b0075","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/tan.12093","article-title":"Common and well-documented HLA alleles: 2012 update to the CWD catalogue","volume":"81","author":"Mack","year":"2013","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.humimm.2020.05.001_b0080","doi-asserted-by":"crossref","first-page":"45553","DOI":"10.1038\/srep45553","article-title":"HLA-B*15:21 and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysis","volume":"7","author":"Jaruthamsophon","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.humimm.2020.05.001_b0085","doi-asserted-by":"crossref","DOI":"10.1038\/nri.2017.143","article-title":"HLA variation and disease","author":"Dendrou","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.humimm.2020.05.001_b0090","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.cll.2018.07.006","article-title":"Human leukocyte antigen typing by next-generation sequencing","volume":"38","author":"Profaizer","year":"2018","journal-title":"Clin. Lab. Med."},{"key":"10.1016\/j.humimm.2020.05.001_b0095","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev-anchem-062012-092628","article-title":"Next-generation sequencing platforms","volume":"6","author":"Mardis","year":"2013","journal-title":"Annu. Rev. Anal. Chem. (Palo Alto Calif.)"},{"key":"10.1016\/j.humimm.2020.05.001_b0100","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1001\/jama.2017.9730","article-title":"Celiac disease and nonceliac gluten sensitivity: a review","volume":"318","author":"Leonard","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.humimm.2020.05.001_b0105","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1146\/annurev-immunol-040210-092915","article-title":"Integration of genetic and immunological insights into a model of celiac disease pathogenesis","volume":"29","author":"Abadie","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.humimm.2020.05.001_b0110","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0198-8859(03)00027-2","article-title":"HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease","volume":"64","author":"Karell","year":"2003","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.humimm.2020.05.001_b0115","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/MPG.0b013e31827913f9","article-title":"Human leukocyte antigen DQ2.2 and celiac disease","volume":"56","author":"Mubarak","year":"2013","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.humimm.2020.05.001_b0120","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/intimm\/10.8.1229","article-title":"The P9 pocket of HLA-DQ2 (non-Aspbeta57) has no particular preference for negatively charged anchor residues found in other type 1 diabetes-predisposing non-Aspbeta57 MHC class II molecules","volume":"10","author":"Quarsten","year":"1998","journal-title":"Int. Immunol."},{"key":"10.1016\/j.humimm.2020.05.001_b0125","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/88694","article-title":"Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes","volume":"2","author":"Lee","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.humimm.2020.05.001_b0130","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1056\/NEJMra1500587","article-title":"Narcolepsy","volume":"373","author":"Scammell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.humimm.2020.05.001_b0135","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5665\/sleep.4342","article-title":"HLA-DQ allele competition in narcolepsy: a comment on Tafti et al. DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe","volume":"38","author":"Ollila","year":"2015","journal-title":"Sleep"},{"key":"10.1016\/j.humimm.2020.05.001_b0140","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1474-4422(08)70140-6","article-title":"CSF hypocretin-1 assessment in sleep and neurological disorders","volume":"7","author":"Bourgin","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.humimm.2020.05.001_b0145","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1056\/NEJMoa1313977","article-title":"Risk of pediatric celiac disease according to HLA haplotype and country","volume":"371","author":"Liu","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.humimm.2020.05.001_b0150","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.cgh.2009.05.028","article-title":"Stratifying risk for celiac disease in a large at-risk United States population by using HLA alleles","volume":"7","author":"Pietzak","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.humimm.2020.05.001_b0155","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.humimm.2012.01.004","article-title":"DQB1*06:02 allele-specific expression varies by allelic dosage, not narcolepsy status","volume":"73","author":"Weiner Lachmi","year":"2012","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.humimm.2020.05.001_b0160","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5665\/sleep.3300","article-title":"DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe","volume":"37","author":"Tafti","year":"2014","journal-title":"Sleep"},{"key":"10.1016\/j.humimm.2020.05.001_b0165","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11926-017-0640-1","article-title":"An update on the genetic polymorphism of HLA-B*27 with 213 alleles encompassing 160 subtypes (and still counting)","volume":"19","author":"Khan","year":"2017","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.humimm.2020.05.001_b0170","doi-asserted-by":"crossref","first-page":"D423","DOI":"10.1093\/nar\/gku1161","article-title":"The IPD and IMGT\/HLA database: allele variant databases","volume":"43","author":"Robinson","year":"2015","journal-title":"Nucl. Acids Res."},{"key":"10.1016\/j.humimm.2020.05.001_b0175","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.molimm.2013.06.013","article-title":"Genetics of ankylosing spondylitis","volume":"57","author":"Robinson","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.humimm.2020.05.001_b0180","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-immunol-032414-112110","article-title":"HLA-B27","volume":"33","author":"Bowness","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.humimm.2020.05.001_b0185","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0140-6736(73)91360-3","article-title":"Ankylosing spondylitis and HL-A 27","volume":"301","author":"Brewerton","year":"1973","journal-title":"The Lancet"},{"key":"10.1016\/j.humimm.2020.05.001_b0190","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJM197304052881403","article-title":"High association of an HL-A antigen, W27, with ankylosing spondylitis","volume":"288","author":"Schlosstein","year":"1973","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.humimm.2020.05.001_b0195","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coi.2012.10.002","article-title":"Human leukocyte antigen-associated drug hypersensitivity","volume":"25","author":"Illing","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.humimm.2020.05.001_b0200","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(02)08158-8","article-title":"Genetic variations in HLA-B region and hypersensitivity reactions to abacavir","volume":"359","author":"Hetherington","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.humimm.2020.05.001_b0205","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nature11147","article-title":"Immune self-reactivity triggered by drug-modified HLA-peptide repertoire","volume":"486","author":"Illing","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.humimm.2020.05.001_b0210","unstructured":"FDA US: Information for Healthcare Professionals: Dangerous or Even Fatal Skin Reactions \u2013 Carbamazepine. Department of Health and Human Services, 2007."},{"key":"10.1016\/j.humimm.2020.05.001_b0215","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1399-0039.2008.01183.x","article-title":"The HLA dictionary 2008: a summary of HLA-A, -B, -C, -DRB1\/3\/4\/5, and -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens","volume":"73","author":"Holdsworth","year":"2009","journal-title":"Tissue Antigens"},{"issue":"43","key":"10.1016\/j.humimm.2020.05.001_b0220","doi-asserted-by":"crossref","first-page":"D784","DOI":"10.1093\/nar\/gku1166","article-title":"Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations","volume":"2015","author":"Gonz\u00e1lez-Galarza Faviel","year":"2015","journal-title":"Nucl. Acids Res."},{"key":"10.1016\/j.humimm.2020.05.001_b0225","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.jaci.2011.12.990","article-title":"Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome","volume":"129","author":"Wei","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.humimm.2020.05.001_b0230","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/iji.12236","article-title":"The dichotomy between disease phenotype databases and the implications for understanding complex diseases involving the major histocompatibility complex","volume":"42","author":"Clark","year":"2015","journal-title":"Int. J. Immunogenet."}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885919314363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885919314363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:52:56Z","timestamp":1759319576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885919314363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0198885919314363"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2020.05.001","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical utility of next generation sequencing based HLA typing for disease association and pharmacogenetic testing","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2020.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}